Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...